These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next

Wall Street’s read on three of 2026’s most volatile names—Moderna (NASDAQ: MRNA), Strategy (NASDAQ: MSTR), and Trade Desk (NASDAQ: TTD)—tells three very different stories. All three have bounced off recent lows, but analyst consensus reveals sharply divergent conviction levels behind each recovery.

Trade Desk: Cautious Optimism After a Brutal Reset

This stock has rebounded 24.38% in the past week to $29.79, but remains 55.23% below where it traded one year ago. The analyst community is split. Of 38 analysts covering the stock, 16 rate it Buy and three Strong Buy, but 15 hold a neutral view and four are outright negative. The consensus price target is $31.89. That is just 7% above current levels, suggesting analysts see limited near-term upside even after the crash.

The underlying business is not broken. Q4 2025 adjusted EPS came in at $0.59 against an estimate of $0.34, a 73.58% beat, while revenue of $846.79 million edged past the $839.55 million consensus. Customer retention held above 95% for the 12th consecutive year. What spooked investors was the deceleration: Q1 2026 guidance calls for revenue of at least $678 million, implying roughly 10% growth, which is a step down from the 18% pace delivered in full-year 2025. For retail investors, the gap between the target price and current levels is thin enough that TTD offers little margin of safety at this valuation unless growth reaccelerates. The stock trades at a forward P/E of 20.83x with a PEG ratio of 0.909. That’s not expensive if growth returns, but analysts aren’t yet pricing in that outcome.

Moderna: Trading Well Above Where Analysts Think It Should Be

Moderna has surged 82.54% year-to-date to $53.83, and the bounce has run well past what Wall Street endorses. The consensus price target is $42.90, or roughly 20% below where the stock trades today. Of 24 analysts covering Moderna, 18 rate it Hold, two Sell, and two Strong Sell, with just three carrying any bullish rating. That is one of the most skeptical analyst distributions in large-cap biotech.

The Q4 beat was real, with EPS of −$2.11 versus an estimate of −$2.62, and revenue of $678 million beating the $612.28 million consensus by 10.73%. And the cost discipline is genuine: operating expenses fell $2.2 billion, or 30%, in 2025. But full-year revenue declined 40% from 2024, and the FDA’s initial refusal-to-file letter on the flu vaccine mRNA-1010 removed a key near-term catalyst. CEO Stéphane Bancel targets cash breakeven by 2028, but with operating cash flow at −$1.873 billion in 2025, the runway depends heavily on pipeline execution. For retail investors, the current price embeds significant optimism around norovirus and melanoma data readouts expected in 2026. Wall Street, by a wide margin, does not share that optimism at this price.

Strategy: The Most Bullish Analyst Consensus of the Three

Shares have bounced from $106 at its Q4 filing to $139.81, yet they remain 54.69% below the price a year ago. Paradoxically, analyst sentiment here is the most bullish of the three: 13 of 14 analysts covering the stock rate it Buy or Strong Buy, with zero Sell ratings. The consensus target is $394.38, implying roughly 182% upside from current levels.

That target is essentially a Bitcoin call. The company holds 713,502 BTC as of February 1, 2026, and the Q4 net loss of $12.44 billion was driven almost entirely by a $17.44 billion unrealized loss on digital assets under fair value accounting — not an operational deterioration. The underlying software business showed subscription services growing 62.1% year-over-year. The risk is structural: over $29 billion in preferred ATM capacity remains available, meaning ongoing dilution is the price of admission.

The takeaway across all three: Strategy has the strongest analyst backing but demands a Bitcoin thesis. Trade Desk’s analyst consensus is directionally positive but priced for modest recovery, not a rerating. Moderna is the clearest case where the stock has outrun the smart money; retail investors buying the bounce here are betting against a heavily skeptical Wall Street consensus at a price that already reflects a best-case pipeline scenario.